Alnylam Pharmaceuticals
ALNY
#647
Rank
ยฃ29.34 B
Marketcap
ยฃ219.83
Share price
0.68%
Change (1 day)
9.33%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): ยฃ0.64 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ4.28 Billion. In 2025 the company made an earning of ยฃ0.47 Billion, an increase over its 2024 earnings that were of -ยฃ0.18 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) ยฃ0.64 B36.66%
2025 ยฃ0.47 B-369.48%
2024 -ยฃ0.18 Billion-24.59%
2023 -ยฃ0.24 Billion-67.84%
2022 -ยฃ0.73 Billion36.93%
2021 -ยฃ0.54 Billion-8.04%
2020 -ยฃ0.58 Billion-15.66%
2019 -ยฃ0.69 Billion12.23%
2018 -ยฃ0.62 Billion62.91%
2017 -ยฃ0.38 Billion17.78%
2016 -ยฃ0.32 Billion43.44%
2015 -ยฃ0.23 Billion60.69%
2014 -ยฃ0.14 Billion98.2%
2013 -ยฃ69.63 Million
2011 -ยฃ41.07 Million27.48%
2010 -ยฃ32.22 Million-10.92%
2009 -ยฃ36.17 Million95.77%
2008 -ยฃ18.48 Million
2006 -ยฃ29.6 Million-9.13%
2005 -ยฃ32.57 Million34.74%
2004 -ยฃ24.17 Million36.79%
2003 -ยฃ17.67 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
ยฃ11.82 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ5.73 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ3.86 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ0.53 Billion-180.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ35.54 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.12 Billion-118.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ1.70 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.25 B-60.31%๐Ÿ‡บ๐Ÿ‡ธ USA